Pfizer Shares Fall 1.7% After CFO Denton’s August Exit, Guegan Named Interim
PFE•Pfizer announced that CFO Dave Denton will leave on August 15 to join the consumer goods industry, prompting a 1.7% share decline. Senior VP Cecile Guegan will take over as interim CFO while the company conducts a search for a permanent successor.
1. CFO Dave Denton’s Departure
Pfizer CFO Dave Denton will leave on August 15 to join the consumer goods industry, concluding a tenure marked by major acquisitions such as Seagen, Biohaven and Metsera. The board emphasized that his exit is voluntary and not due to financial or operational issues.
2. Interim CFO Appointment
Senior Vice President Cecile Guegan has been named interim CFO effective August 16, leveraging over 20 years of finance leadership within Pfizer across global biopharmaceutical operations. She will oversee financial reporting, budgeting and integration while a permanent successor is sought.
3. Shareholder Reaction and Market Impact
Pfizer shares declined 1.7% following the announcement as investors weighed leadership changes during ongoing strategic transformations. The move underscores concerns over continuity amid integration of recent acquisitions and long-term financial guidance.
4. Search for Permanent Successor
The company has launched a comprehensive review of internal and external candidates for the permanent CFO role, planning to ensure seamless transition and maintain financial strategy. Denton and Guegan will collaborate through mid-August to facilitate knowledge transfer.
